Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.

Li Fraumeni Syndrome (LFS) is a multicancer phenotype, most commonly associated with germ-line mutations in TP53. In a kindred with LFS without an inherited TP53 mutation, we have previously reported a truncating mutation (1100delC) in CHK2, encoding a kinase that phosphorylates p53 on Ser(20). Here, we describe a CHK2 missense mutation (R145W) in another LFS family. This mutation destabilizes the encoded protein, reducing its half-life from >120 min to 30 min. This effect is abrogated by treatment of cells with a proteosome inhibitor, suggesting that CHK2(R145W) is targeted through this degradation pathway. Both 1100delC and R145W germ-line mutations in CHK2 are associated with loss of the wild-type allele in the corresponding tumor specimens, and neither tumor harbors a somatic TP53 mutation. Our observations support the functional significance of CHK2 mutations in rare cases of LFS and suggest that such mutations may substitute for inactivation of TP53.

[1]  Jay H. Chung,et al.  The hCds1 (Chk2)-FHA Domain Is Essential for a Chain of Phosphorylation Events on hCds1 That Is Induced by Ionizing Radiation* , 2001, The Journal of Biological Chemistry.

[2]  R. Winqvist,et al.  Mutation analysis of the CHK2 gene in families with hereditary breast cancer , 2001, British Journal of Cancer.

[3]  N. Mailand,et al.  The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis , 2001, Nature.

[4]  Jing Chen,et al.  Characterization of Tumor-associated Chk2 Mutations* , 2001, The Journal of Biological Chemistry.

[5]  S. Elledge,et al.  The DNA damage response: putting checkpoints in perspective , 2000, Nature.

[6]  N. Rhind,et al.  Chk1 and Cds1: linchpins of the DNA damage and replication checkpoint pathways. , 2000, Journal of cell science.

[7]  D. Durocher,et al.  The molecular basis of FHA domain:phosphopeptide binding specificity and implications for phospho-dependent signaling mechanisms. , 2000, Molecular cell.

[8]  H. Konishi,et al.  Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. , 2000, Cancer research.

[9]  R. Eeles,et al.  Screening hCHK2 for mutations. , 2000, Science.

[10]  S. Elledge,et al.  DNA damage-induced activation of p53 by the checkpoint kinase Chk2. , 2000, Science.

[11]  Jong-Soo Lee,et al.  hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response , 2000, Nature.

[12]  T. Halazonetis,et al.  Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. , 2000, Genes & development.

[13]  Y Taya,et al.  The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. , 2000, Genes & development.

[14]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[15]  H. Piwnica-Worms,et al.  A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Blasina,et al.  A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase , 1999, Current Biology.

[17]  S. Elledge,et al.  Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. , 1998, Science.

[18]  S N Thibodeau,et al.  Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. , 1998, Nucleic acids research.

[19]  D. Evans,et al.  Li-Fraumeni syndrome--a molecular and clinical review. , 1997, British Journal of Cancer.

[20]  A. Craft,et al.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. , 1994, Cancer research.

[21]  A. Thor,et al.  p53 gene mutations and protein accumulation in human ovarian cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. Koeffler,et al.  Mutations of the p53 gene in adult T-cell leukemia. , 1992, Blood.

[23]  J. Fraumeni,et al.  Follow-up study of twenty-four families with Li-Fraumeni syndrome. , 1991, Cancer research.

[24]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[25]  T. Hunter,et al.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.

[26]  J. Fraumeni,et al.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.